Dr. Overman on Remaining Questions With Immunotherapy in CRC

Michael J. Overman, MD
Published: Tuesday, Feb 20, 2018



Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the remaining questions with immunotherapy in colorectal cancer (CRC).

The updated findings from the CheckMate-142 study continue to support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic CRC. However, there is still a large proportion of patients with CRC who do not respond to immunotherapy.

Overman says that investigators are aiming to answer the question of how to do better in this group, and how to apply it to the majority of patients with CRC. There is ongoing work to identify how to move forward with immunotherapy in patients with CRC, Overman says, but there is still a lot that needs to be done. Combinations could be an avenue, but there needs to be more data to make a definitive statement.


Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the remaining questions with immunotherapy in colorectal cancer (CRC).

The updated findings from the CheckMate-142 study continue to support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic CRC. However, there is still a large proportion of patients with CRC who do not respond to immunotherapy.

Overman says that investigators are aiming to answer the question of how to do better in this group, and how to apply it to the majority of patients with CRC. There is ongoing work to identify how to move forward with immunotherapy in patients with CRC, Overman says, but there is still a lot that needs to be done. Combinations could be an avenue, but there needs to be more data to make a definitive statement.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x